BMS-986158 With or Without Ruxolitinib or Fedratinib in Intermediate/High-Risk Myelofibrosis

Phase 2, open-label trial of 2-(3-(3,5-dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido[3,2-b]indol-7-yl)propan-2-ol in myelofibrosis (MF), post-essential thrombocythemia myelofibrosis (PET-MF) and post-polycythemia vera myelofibrosis (PPV-MF) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of adverse events, serious adverse events, dose-limiting toxicities, and adverse events leading to discontinuation and death. Planned start Jan 2024; status: authorised.